Evidence map›Paper›PMID 30142943›Full record

SynthesisNutrients2018

Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence.

Arrigo F G Cicero, Alessandro Colletti, Stefano Bellentani

Open access · goldAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Nutrients, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 4 pooled it
14.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 4 syntheses or guidelines pooled it, 177 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. AltilixNutrients · 2019
    Trial
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Arrigo F G CiceroItalian Society of Nutraceuticals (SINut), Medical and Surgical Science Department, University of Bologna, 40138 Bologna, Italy. arrigo.cicero@unibo.it.ORCID 0000-0002-4367-3884
Alessandro CollettiItalian Society of Nutraceuticals (SINut), Medical and Surgical Science Department, University of Bologna, 40138 Bologna, Italy. dott.alessandro.colletti@gmail.com.
Stefano BellentaniGastroenterology and Hepatology Service-Clinica Santa Chiara, 6604 Locarno, Switzerland. bellentanistefano@gmail.com.
University of Bologna · ITOspedale Regionale di Locarno · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a clinical condition characterized by lipid infiltration of the liver, highly prevalent in the general population affecting 25% of adults, with a doubled prevalence in diabetic and obese patients. Almost 1/3 of NAFLD evolves in Non-Alcoholic SteatoHepatitis (NASH), and this can lead to fibrosis and cirrhosis of the liver. However, the main causes of mortality of patients with NAFLD are cardiovascular diseases. At present, there are no specific drugs approved on the market for the treatment of NAFLD, and the treatment is essentially based on optimization of lifestyle. However, some nutraceuticals could contribute to the improvement of lipid infiltration of the liver and of the related anthropometric, haemodynamic, and/or biochemical parameters. The aim of this paper is to review the available clinical data on the effect of nutraceuticals on NAFLD and NAFLD-related parameters. Relatively few nutraceutical molecules have been adequately studied for their effects on NAFLD. Among these, we have analysed in detail the effects of silymarin, vitamin E, vitamin D, polyunsaturated fatty acids of the omega-3 series, astaxanthin, coenzyme Q10, berberine, curcumin, resveratrol, extracts of

Indexed as

Dietary SupplementsAntioxidantsBerberineCurcuminFatty Acids, Omega-3Fatty Acids, UnsaturatedHumansMeta-Analysis as TopicNon-alcoholic Fatty Liver DiseaseObesityObservational Studies as TopicPlant ExtractsProbioticsRandomized Controlled Trials as TopicResveratrolSalvia miltiorrhizaAntioxidantsastaxanthineBerberinecoenzyme Q10CurcuminFatty Acids, Omega-3Fatty Acids, UnsaturatedPlant ExtractsResveratrolSilymarinUbiquinoneVitamin DVitamin EXanthophyllsclinical trialsdietary supplementsNAFLDnutraceuticals

Identifiers

PMID30142943
PMCPMC6163782
OpenAlexW2888443845

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.